Methods of treating lupus using CD4 antibodies
An antibody and lupus technology, applied in the field of treating lupus with CD4 antibody, can solve dangerous and complicated problems
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
Example 1: Treatment of lupus with non-depleting CD4 antibodies alone or in combination
[0230] A series of experiments are listed below to demonstrate that non-depleting CD4 antibodies are effective in preclinical models of SLE. The performance of the antibody is compared to exemplary standards of care and experimental treatments.
[0231] NZBxW F1 mice exhibit spontaneous lupus-like nephropathy, providing a useful preclinical efficacy model of SLE (see, e.g., Theofilopoulos (1992) "Murine models of systemic lupus erythematosus (murine models of systemic lupus erythematosus)", selected from Systemic Lupus Erythematosus (Systemic Lupus Erythematosus), Lahita (ed.) Churchill Livingstone, New York, 121-194). Figure 5 Schematic representation of disease progression with age in this model. Observed symptoms included the development of ds-DNA antibodies, proteinuria, renal histopathology, elevated blood urea nitrogen (BUN), and increased mortality. Arrows indicate the time point...
Embodiment 2
Example 2: Treatment of multiple sclerosis with non-depleting CD4 antibodies
[0254] Listed below is a series of experiments demonstrating the efficacy of non-depleting CD4 antibodies in preclinical models of MS. The performance of the antibodies is compared to exemplary standards of care and experimental treatments.
[0255] Experimental allergic encephalomyelitis (EAE) is an inflammatory disorder of the central nervous system (CNS) similar to MS; in both diseases, demyelination leads to impaired nerve conduction and paralysis. Relapsing and relapsing EAE induced by injection of proteolipid protein (PLP) peptides into SJL / J mice provides a useful preclinical efficacy model of MS (see, e.g., Miller and Karpus (1996) "Experimental Autoimmune Encephalomyelitis in the Mouse (Experimental Allergic Encephalomyelitis in Mice)" In Current Protocols in Immunology, Coligan et al (eds), John Wiley & Sons, and Sobel et al, (1990)" Acute experimental allergic encephalomyelitis in SJL / J ...
Embodiment 3
Example 3: The combination of CD4 antibody and MMF treats lupus
[0273] Listed below is a series of experiments demonstrating the efficacy of non-depleting CD4 antibodies alone or in combination with mycophenolate mofetil in preclinical models of SLE.
[0274] The NZB x W F1 mouse model of SLE is as described in Example 1. In this model, the preclinical efficacy of a non-depleting CD4 antibody (YTS177, described above) was compared with that of a nonbinding control antibody (described above), mycophenolate mofetil ( or MMF, current therapeutics) and the combination of CD4 antibody and MMF.
[0275] Treatment of NZB x NZW mice was started at 9 months of age. The mice were screened for proteinuria and randomly grouped according to their proteinuria scores. At the start of the experiment, each treatment group consisted of 15 mice, 73% of which showed proteinuria levels >300 mg / dl. (Note that this disease state is more severe than that at the start of treatment in the experim...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com